MarketSheet

Streamline Indication Prioritization

A decision support tool of concise one-page indication summaries that enable triage of potential indications for product development

LEARN MORE

Metrics Covered in MarketSheet

MarketSheet

Selecting target indications for product development can be a complex process. REACH’s MarketSheet is a decision support tool designed to address this complexity and expedite indication prioritization.

MarketSheet delivers succinct­­, one-page indication summaries that encompass key commercial, market, clinical, and scientific parameters. These summaries expedite the initial assessment of potential indications, allowing for a more focused allocation of resources towards a smaller number of select indications that warrant in-d­epth analysis.

The underlying research methodology draws from key opinion leader (KOL) insights, extensive literature review, and rigorous analysis of secondary data sources. Employing a systematic and objective approach, our MarketSheets enable you to triage, rank, and winnow down a long list of potential indications in a data-driven manner.

Review sample content

CLINICAL FEASIBILITY


  • Clinical trial parameters
  • Complexity of endpoints
  • Surrogate endpoints

COMMERCIAL ATTRACTIVENESS


  • Size of addressable population
  • Current standard of care
  • Level of unmet need
  • Pricing potential

MARKET FACTORS


  • Regulatory precedent
  • Future competition
  • Threat of generic entry

SCIENTIFIC EVIDENCE


  • Evidence of druggable target(s)

MarketSheet

Selecting target indications for product development can be a complex process. REACH’s MarketSheet is a decision support tool designed to address this complexity and expedite indication prioritization.

MarketSheet delivers succinct­­, one-page indication summaries that encompass key commercial, market, clinical, and scientific parameters. These summaries expedite the initial assessment of potential indications, allowing for a more focused allocation of resources towards a smaller number of select indications that warrant in-d­epth analysis.

The underlying research methodology draws from key opinion leader (KOL) insights, extensive literature review, and rigorous analysis of secondary data sources. Employing a systematic and objective approach, our MarketSheets enable you to triage, rank, and winnow down a long list of potential indications in a data-driven manner.

Review sample content

Metrics Covered in MarketSheet

CLINICAL FEASIBILITY


  • Clinical trial parameters
  • Complexity of endpoints
  • Surrogate endpoints

COMMERCIAL ATTRACTIVENESS


  • Size of addressable population
  • Current standard of care
  • Level of unmet need
  • Pricing potential

MARKET FACTORS


  • Regulatory precedent
  • Future competition
  • Threat of generic entry

SCIENTIFIC EVIDENCE


  • Evidence of druggable target(s)

A LOOK INSIDE MARKETSHEET

Disease Coverage

Any disease or list of diseases

Geographic Scope

United States

Delivery Timeline

3 weeks for up to 20 indications

What our clients are saying

A LOOK INSIDE MARKETSHEET

Disease Coverage

Any disease or list of diseases

Geographic Scope

United States

Delivery Timeline

3 weeks for up to 20 indications

TRUSTED BY TOP-TIER PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES

It was great to see you at your market access pulse survey readout on Wednesday! The team’s feedback has been consistently very positive with the product quality, Melissa’s expertise, and the process getting the research completed on time. I’m so glad that [name] has you as an obvious go-to-choice for ad hoc requests for [our product].

Sr. Manager, Commercial Analytics

For us, MarketVue® is very valuable to get fast reports and at the right level of detail. We were originally supposed to develop disease strategies but then we had a reorganization and resources were constrained. REACH is a great help to us.

Konstanze Binder

Principal, Global Asset Maximization · LEO Pharma

I need something beyond what I can do for myself with Google and without paying an extraordinary amount of money… MarketVue® goes even further — it’s not your typical syndicated report. It was very collaborative. REACH operates with the best aspects of primary research but then benefits like speed of syndicated reports.

Tony Russell

Director, Commercial Development · Pfizer

With MarketVue® reports, you can get 80-90% of output for 10% of the cost [of custom consulting] — this is great, especially for small clients like us whose budgets are tight, and we don’t have a ton of FTEs. I’m a team of 1. I can’t blow my whole budget on a single question.

Joe Pirrello

Executive Director, Business Development · Astria Therapeutics

Regarding the [rare disease] development program related to our project before the break, I don’t recall if I ever relayed the message – folks were very complimentary of the supportive market research, so THANK YOU very much for a very successful and timely engagement. Let’s stay in touch over the coming weeks on any imminent projects that may materialize on our end.

Director, New Product Commercialization

Before even getting to the MarketVue® product, the process is a huge plus for them. The fact that we can get a tailored report with essentially a proprietary set of questions at that price range with that level of engagement with the team is hugely valuable and gives us a lot of trust with what we receive. MarketVue® is really high quality in general and comparable to much more expensive reports where you get a 100-page report — in terms of value for the amount we use it, it is comparable to much, much more expensive research… They’re really good at highlighting what is most relevant.

Julia Chornak

Senior Manager, Market Insights · Chinook Therapeutics

BTW – I wanted to tell you that the chatter with the [rapid insights] work you just delivered within our NPC team is that you killed it. So, I anticipate you will be our go to for much more work like this in the future.

Director, Pipeline/New Product Commercialization

REACH reports give you the ability to tailor the research a little bit more. I work in rare disease where [syndicated reports] just don’t exist and if they do, they’re not built out. For folks like myself, there is limited ability to use those off-the-shelf reports since they’re focused on mass market. I value the REACH team’s ability and willingness to answer follow up questions, dive in around specific topics, push back on the report, and think critically with us around the implications of the findings… I eventually asked them to synthesize all of our email back/forth into a separate report because I thought it was so useful and thoughtful.

Joe Pirrello

Executive Director, Business Development · Astria Therapeutics

What pushed me over the edge was that they have a nice way of presenting the findings in the end. Sometimes you get a wall of text. Their output was very clean and useful for putting into our slides. I’ve worked with a lot of vendors, and it can be pretty hit or miss. Some vendors can be good at executing, but REACH can be a thought partner. They can take what we’re saying and riff off of us, then come up with additional ideas and put them in front of us.

Kathleen Davenport

Senior Director, New Product Planning · Surface Oncology